Patents by Inventor Stefano Luca Giaffreda

Stefano Luca Giaffreda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10836727
    Abstract: The present invention provides novel crystalline forms of 4-[3-Chloro-4-(N?-cyclopropylureido)phenoxy]-7-methoxyquinoline-6-carboxamide methanesulfonate, as well as methods for their preparation.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: November 17, 2020
    Assignee: Indena S.P.A.
    Inventors: Nicola Sardone, Stefano Luca Giaffreda, Andrea Gambini, Alex Petrolati, Pietro Allegrini, Enrico Modena
  • Patent number: 10815257
    Abstract: The present invention relates to a novel crystalline hemihydrate polymorph of neridronic acid sodium salt, and a novel process for the preparation thereof comprising the steps of: 1) dissolving solid sodium neridronate in any crystalline form in water, at a temperature in the range from 70 to 90° C., to obtain an aqueous solution of sodium neridronate; 2) adding a solvent selected from the group consisting in ethanol, 1-propanol, and 2-propanol to the aqueous solution obtained from step (1), so that the final water:solvent volume ratio is in the range from 1:0.5 to 1:1, thus obtaining a suspension; 3) placing the suspension obtained from step (2) under mechanical stirring, at a temperature in the range from 60 to 95° C.; 4) recovering the crystalline hemihydrate form F of sodium neridronate formed in the previous step (3).
    Type: Grant
    Filed: April 10, 2019
    Date of Patent: October 27, 2020
    Assignee: ABIOGEN PHARMA S.P.A.
    Inventors: Laura Dini, Fabio Neggiani, Barbara Politi, Stefano Luca Giaffreda, Alex Petrolati, Michel Chiarucci, Serena Fabbroni, Kesheng Zhang, Michael Roeder
  • Publication number: 20200276208
    Abstract: Disclosed herein is an oxalate salt/co-crystal (tianeptine oxalate) of (RS)-7-(3-chloro-6-methyl-6,11-dihydrodibenzo[c,f] [1,2]thiazepin-11-ylamino)heptanoic acid S,S-dioxide (tianeptine) as shown in Formula I:
    Type: Application
    Filed: October 9, 2019
    Publication date: September 3, 2020
    Inventors: Stefano Luca Giaffreda, Enrico Modena, Serena Fabbroni, Michel Chiarucci, Mark T. Edgar
  • Publication number: 20200270193
    Abstract: Described herein are polymorphic forms of 1,6-dibromo-1,6-dideoxy-dulcitol (dibromo dulcitol or DBD), which is a known antitumor agent. Also described are methods of making these new crystalline polymorphic forms as well as methods of using these polymorphic forms to treat cancer.
    Type: Application
    Filed: May 12, 2020
    Publication date: August 27, 2020
    Applicant: Targent, LLC
    Inventors: Stefano Luca Giaffreda, Elena Dichiarante
  • Patent number: 10654783
    Abstract: Described herein are polymorphic forms of 1,6-dibromo-1,6-dideoxy-dulcitol (dibromo dulcitol or DBD), which is a known antitumor agent. Also described are methods of making these new crystalline polymorphic forms as well as methods of using these polymorphic forms to treat cancer.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: May 19, 2020
    Assignee: Targent, LLC
    Inventors: Stefano Luca Giaffreda, Elena Dichiarante
  • Patent number: 10449203
    Abstract: Disclosed herein is an oxalate salt/co-crystal (tianeptine oxalate) of (RS)-7-(3-chloro-6-methyl-6,11-dihydrodibenzo[c,f] [1,2]thiazepin-11-ylamino)heptanoic acid S,S-dioxide (tianeptine) as shown in Formula I:
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: October 22, 2019
    Assignee: Tonix Pharma Holdings Limited
    Inventors: Stefano Luca Giaffreda, Enrico Modena, Serena Fabbroni, Michel Chiarucci, Mark T. Edgar
  • Publication number: 20190308999
    Abstract: The present invention relates to a novel crystalline hemihydrate polymorph of neridronic acid sodium salt, and a novel process for the preparation thereof comprising the steps of: 1) dissolving solid sodium neridronate in any crystalline form in water, at a temperature in the range from 70 to 90° C., to obtain an aqueous solution of sodium neridronate; 2) adding a solvent selected from the group consisting in ethanol, 1-propanol, and 2-propanol to the aqueous solution obtained from step (1), so that the final water:solvent volume ratio is in the range from 1:0.5 to 1:1, thus obtaining a suspension; 3) placing the suspension obtained from step (2) under mechanical stirring, at a temperature in the range from 60 to 95° C.; 4) recovering the crystalline hemihydrate form F of sodium neridronate formed in the previous step (3).
    Type: Application
    Filed: April 10, 2019
    Publication date: October 10, 2019
    Applicant: ABIOGEN PHARMA S.P.A.
    Inventors: Laura Dini, Fabio Neggiani, Barbara Politi, Stefano Luca Giaffreda, Alex Petrolati, Michel Chiarucci, Serena Fabbroni, Kesheng Zhang, Michael Roeder
  • Publication number: 20190256473
    Abstract: The present invention provides novel crystalline forms of 4-[3-Chloro-4-(N?-cyclopropylureido)phenoxy]-7-methoxyquinoline-6-carboxamide methanesulfonate, as well as methods for their preparation.
    Type: Application
    Filed: September 15, 2017
    Publication date: August 22, 2019
    Applicant: Indena S.P.A.
    Inventors: Nicola Sardone, Stefano Luca Giaffreda, Andrea Gambini, Alex Petrolati, Pietro Allegrini, Enrico Modena
  • Publication number: 20180362427
    Abstract: Described herein are polymorphic forms of 1,6-dibromo-1,6-dideoxy-dulcitol (dibromo dulcitol or DBD), which is a known antitumor agent. Also described are methods of making these new crystalline polymorphic forms as well as methods of using these polymorphic forms to treat cancer.
    Type: Application
    Filed: June 15, 2016
    Publication date: December 20, 2018
    Applicant: Targent, LLC
    Inventors: Stefano Luca Giaffreda, Elena Dichiarante
  • Publication number: 20180338984
    Abstract: Disclosed herein is an oxalate salt/co-crystal (tianeptine oxalate) of (RS)-7-(3-chloro-6-methyl-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-ylamino)heptanoic acid S,S-dioxide (tianeptine) as shown in Formula I:
    Type: Application
    Filed: December 28, 2017
    Publication date: November 29, 2018
    Inventors: Stefano Luca Giaffreda, Enrico Modena, Serena Fabbroni, Michel Chiarucci, Mark T. Edgar
  • Publication number: 20170275264
    Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: March 7, 2017
    Publication date: September 28, 2017
    Applicant: NOVARTIS AG
    Inventors: Yves AUBERSON, Mark Gary BOCK, Dario BRAGA, Marco CURZI, Stephanie Kay DODD, Stefano Luca GIAFFREDA, Haiyang JIANG, Piotr KARPINSKI, Thomas J. TROXLER, Tie-Lin WANG, Xiaoyang WANG, Xuechun ZHANG
  • Patent number: 9687484
    Abstract: The present invention relates to novel crystalline forms of vortioxetine hydrobromide, in particular three crystalline forms, a process for their preparation, a pharmaceutical composition containing said novel crystalline forms, and a process for the purification of vortioxetine or a salt thereof, comprising the formation of one or more of the novel crystalline forms of vortioxetine hydrobromide described herein.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: June 27, 2017
    Assignee: Dipharma Francis S.r.l.
    Inventors: Stefano Luca Giaffreda, Marco Curzi, Elena Dichiarante, Pietro Allegrini, Renzo Graziosi, Chiara Vladiskovic
  • Patent number: 9624192
    Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: April 18, 2017
    Assignee: Novartis AG
    Inventors: Yves Auberson, Mark Gary Bock, Dario Braga, Marco Curzi, Stephanie Kay Dodd, Stefano Luca Giaffreda, Haiyang Jiang, Piotr Karpinski, Thomas J. Troxler, Tie-Lin Wang, Xiaoyang Wang, Xuechun Zhang
  • Publication number: 20160244426
    Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: February 22, 2016
    Publication date: August 25, 2016
    Applicant: NOVARTIS AG
    Inventors: Yves AUBERSON, Mark Gary BOCK, Dario BRAGA, Marco CURZI, Stephanie Kay DODD, Stefano Luca GIAFFREDA, Hayang JIANG, Piotr KARPINSKI, Thomas J. TROXLER, Tie-Lin WANG, Xiaoyang WANG, Xuechun ZHANG
  • Publication number: 20160193165
    Abstract: Novel polymorphic forms and salts of 1-(3?,4?-dichloro-2-fluorobiphenyl-4-yl)cyclopropanecarboxylic acid are useful for the prevention or treatment of Alzheimer's Disease.
    Type: Application
    Filed: March 17, 2016
    Publication date: July 7, 2016
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Fausto PIVETTI, Maurizio DELCANALE, Stefano Luca GIAFFREDA, Marco CURZI
  • Patent number: 9273026
    Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: March 1, 2016
    Assignee: Novartis AG
    Inventors: Yves Auberson, Mark Gary Bock, Dario Braga, Marco Curzi, Stephanie Kay Dodd, Stefano Luca Giaffreda, Hayang Jiang, Piotr Karpinski, Thomas J. Troxler, Tie-Lin Wang, Xiaoyang Wang, Xuechun Zhang
  • Publication number: 20160015706
    Abstract: The present invention relates to novel crystalline forms of vortioxetine hydrobromide, in particular three crystalline forms, a process for their preparation, a pharmaceutical composition containing said novel crystalline forms, and a process for the purification of vortioxetine or a salt thereof, comprising the formation of one or more of the novel crystalline forms of vortioxetine hydrobromide described herein.
    Type: Application
    Filed: July 6, 2015
    Publication date: January 21, 2016
    Applicant: DIPHARMA FRANCIS S.r.l.
    Inventors: Stefano Luca GIAFFREDA, Marco CURZI, Elena DICHIARANTE, Pietro ALLEGRINI, Renzo GRAZIOSI, Chiara VLADISKOVIC
  • Publication number: 20150218127
    Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: April 14, 2015
    Publication date: August 6, 2015
    Applicant: NOVARTIS AG
    Inventors: Yves AUBERSON, Mark Gary BOCK, Dario BRAGA, Marco CURZI, Stephanie Kay DODD, Stefano Luca GIAFFREDA, Hayang JIANG, Piotr KARPINSKI, Thomas J. TROXLER, Telin WANG, Xiaoyang WANG, Xuechun ZHANG
  • Patent number: 9034874
    Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Grant
    Filed: July 17, 2013
    Date of Patent: May 19, 2015
    Assignee: NOVARTIS AG
    Inventors: Yves Auberson, Mark Gary Bock, Dario Braga, Marco Curzi, Stephanie Kay Dodd, Stefano Luca Giaffreda, Haiyang Jiang, Piotr Karpinski, Thomas J. Troxler, Tielin Wang, Xiaoyang Wang, Xuechun Zhang
  • Publication number: 20140163036
    Abstract: The invention relates to compound of the formula I or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: July 17, 2013
    Publication date: June 12, 2014
    Inventors: Yves AUBERSON, Mark Gary Bock, Dario Braga, Marco Curzi, Stephanie Kay Dodd, Stefano Luca Giaffreda, Haiyang Jiang, Piotr Karpinski, Thomas J. Troxler, Tielin Wang, Xiaoyang Wang, Xuechun Zhang